ClinicalTrials.gg
CompletedNCT05288400Updated Jun 5, 2025

Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

A Phase 3 interventional study of Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg and Norvasc 5mg tablet in Essential Hypertension, sponsored by Servier. Completed at 15 sites in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Servier · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled May 2018, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Enrollment
24th of 34
150 · median 314
Started
2018
the only one that year
Phase 3
18 of 34
none open now
Registered
28th of 34
by date

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 24th largest by enrollment, is the only one that started in 2018, is one of 18 in phase 3, and was the 28th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and the safety of a fixed-dose combination in capsule of Amlodipine 5mg/ Bisoprolol fumarate 5mg/ Perindopril arginine 5mg, and free monotherapy at the same dose in patients with uncontrolled essential hypertension.

Read the detailed description

This was a phase III, multicenter, randomized, open-label, controlled study, over a 12-week treatment period with a single-capsule of fixed dose combination (FDC) of Amlodipine 5 mg/ Bisoprolol fumarate 5 mg / Perindopril arginine 5 mg and free monocomponents of Amlodipine 5 mg, Bisoprolol fumarate 5 mg and Perindopril arginine 5 mg given concomitantly, in 150 patients with uncontrolled essential HT.

Patients without any non-selection criteria, already treated by anti-hypertensive monotherapy at maximal dose or either by a dual therapy at minimum dose, other than study treatment, having an uncontrolled HT defined by SBP (Systolic Blood Pressure) ≥ 140 and \<160 mmHg and DBP (Diastolic Blood Pressure) ≥ 90 and \<100 mmHg (in supine position) at 2 different visits (selection and inclusion) were to be selected in this study and randomized to one of two treatment groups: single-capsule combination or free therapy without any wash-out period.

For all patients, controlled blood pressure (BP) was defined as SBP \< 140 mmHg and DBP \< 90 mmHg.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Selection criteria:

  • Men or women of any ethnic origin ≥18 years old who signed form.
  • Patients with uncontrolled hypertension defined by SBP ≥140 and \< 160 mmHg and DBP ≥90 and \< 100 mmHg already treated by anti-hypertensive monotherapy at maximal dose or either by a dual therapy at minimum dose, other than study treatment (amlodipine or bisoprolol or perindopril), for at least 4 weeks.
  • Women of potential childbearing and men (and/or their partners) must agree to use appropriate measures. This applies since signing of the Informed Consent form until the last study drug administration.
  • Willing to provide signed and dated informed consent.

Non selection criteria

  • Unlikely to co-operate in the study, to comply with study treatment or with the study visits.
  • Pregnancy, breastfeeding.
  • Current participation in another randomized study or within the preceding 3 months.
  • Participant already enrolled in the study.
  • Alcohol or drug abuse and/or dependence.
  • > 32 kg/m².
  • Grapefruit juice was forbidden during the study (interaction with amlodipine).

Concerning Hypertension (HT)

  • DBP ≥100 mmHg and/or SBP ≥160 mmHg under treatment.
  • Known or suspected symptomatic orthostatic hypotension.
  • HT known to be resistant to Calcium Channel Blockers or Angiotensin Converting Enzyme (ACE) inhibitors or Beta Blockers.
  • Secondary HT.
  • Complicated HT: known stage III or IV hypertensive retinopathy, macroalbuminuria (patients with microalbuminuria could be selected).

Concerning concomitant diseases

  • History of renal disease: Known renal impairment: Patients having a value classifying them as moderate or severe renal failure (using national or international classification of chronic kidney disease), whatever the method for calculation used (Modification of Diet in Renal Disease () or Cockcroft or any other Estimated Glomerular Filtration Rate (eGFR) formula), or bilateral renal artery stenosis or stenosis to a solitary kidney.
  • History of cerebrovascular disease: ischemic stroke, cerebral hemorrhage, .
  • History of heart disease: shock (including cardiogenic), myocardial infarction (within previous 6 months before selection), heart failure class II to IV (New York Heart Association), coronary revascularization (within the previous 6 months), severe aortic or mitral valve stenosis or hypertrophic obstructive myocardiopathy, unstable angina pectoris (including Prinzmetal's angina).
  • History of recent (within previous 6 months before selection, accordingly to the doctor decision) ventricular rhythm disorders (except isolated extrasystoles), atrial fibrillation or atrial flutter, second or third degree atrioventricular (AV) block or other cardiac rhythm disorders leading to important beat-to-beat variations in BP (Left Ventricular Hypertrophy was authorized at selection and during the study).
  • Known prolonged .
  • Patients having resting HR \<50 bpm.
  • History of sick sinus syndrome.
  • History of bradycardia episode.
  • Severe forms of peripheral arterial occlusive disease or severe forms of Raynaud's syndrome.
  • Severe bronchial asthma or severe .
  • Severe gastro-intestinal tract disorders with possible influence on drug absorption or electrolytes.
  • Known complicated liver disease (for example: chronic hepatitis, cirrhosis, hepatic encephalopathy...).
  • Chronic pancreatitis.
  • Endocrine diseases: uncontrolled dysthyroidia, Cushing's syndrome, acromegalia, hyperparathyroidia.
  • Diabetes mellitus type I and type II under treatment (patients with diabetes type II well controlled at the selection visit by lifestyle and dietary rules alone could be selected).
  • Any history or known severe disease likely to interfere with the conduct of the study, severe evolutive infection, evolutive malignant neoplasm.
  • History of neutropenia.
  • History of connective tissue disorders (systemic lupus erythematosus, progressive systemic sclerosis or other connective tissue disorders).
  • History of severe mental or psychiatric disorder, severe depression or history of severe depression, e.g. requiring hospitalization or at high risk of suicide attempt.
  • History of angioneurotic oedema.

Concerning concomitant medications

  • β-blockers even if used for other reason than HT, in order to avoid the AE related to the immediate switch during selection visit.
  • Antihypertensive treatments having central mechanism of action in order to avoid possible rebound effect at a full immediate stop at the randomization.
  • Antiarrhythmic treatments in order to avoid possible interactions with bisoprolol.
  • Inability to stop any of the medications listed in the prohibited concomitant medication list.
  • Potassium supplement at selection and inclusion visit.
  • Drugs with the study treatments as defined in the Summaries of Product Characteristics of each study drugs

Concerning contra-indications to treatment with amlodipine, bisoprolol or perindopril

  • Any history of angioedema, hereditary, idiopathic or associated with previous ACE inhibitor therapy.
  • Allergy / / history of intolerance or any contra-indications related to:

    • amlodipine or any other dihydropyridine and calcium inhibitors;
    • perindopril or any other ACE inhibitor;
    • bisoprolol or other beta-blockers;
    • any of the of the study drugs.

Inclusion criteria

Inclusion criteria :

  • Respect of the previous selection and non-selection criteria.
  • Confirmed essential uncontrolled HT under patient's current treatment at W000 visit, defined as SBP ≥140 and \< 160 mmHg and DBP ≥90 and \< 100 mmHg, measured with a validated automatic device in supine position after at least 10 minutes of rest. There were 3 BP measurements at 2-3 minutes of an interval between each measurement. The mean of the two last values of the three measurements was taken.
  • Normal or without any clinically significant abnormality 12-lead (left ventricular hypertrophy and post-MI ECG-changes are authorized at selection and during the study).
  • Normal or without clinically significant abnormality of laboratory examinations. Microalbuminuria was authorized.

Non-inclusion criteria :

  • As per non-selection criteria.
  • Occurrence of an event requiring immediate notification since Selection.
  • Laboratory results unavailable at the inclusion visit.
  • Withdrawal of informed consent by patient.
  • DBP ≥100 mmHg and/or SBP ≥160 mmHg under treatment since the selection visit.
  • Positive orthostatic test at inclusion.
  • Positive β-human Chorionic Gonadotrophin (β-HCG) pregnancy test (Blood test).
  • Laboratory results unavailable at the inclusion visit or clinically significant abnormalities. Macroalbuminuria (>300 mg albumin/24h) was not authorized. ASpartate (Amino)Transferase (ASAT) or ALanine (Amino)Transferase (ALAT) ≥ 2 UNL (Upper Normal Limit) was not authorized.

If all Inclusion and non-inclusion criteria were satisfied, the patient was included and randomized to a treatment group.

Exclusion criteria

Exclusion Criteria (withdrawal criteria) :

  • Patients whose BP was still uncontrolled at two consecutive visits (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) or whose SBP/DBP was above 160/100 mmHg (confirmed with 2 consecutive visits starting W004, at least 14 days apart).
  • Onset of an adverse event (AE) which required prescription of a treatment incompatible with the protocol.
  • Onset of an AE which, according to the investigator, makes it unsafe for the patient to continue with the study treatment. This includes abnormal biochemical and haematological parameters, or clinically significant abnormality.
  • Pregnancy.
  • Major protocol deviation preventing the analysis of the main endpoint, or which, in the opinion of the investigator, makes it unsafe for the patient to continue to take the study medication and to stay in the study.
  • Non-medical reason (patient's personal decision to stop treatment).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Group A

    single-capsule of fixed dosed combination (FDC) of amlodipine 5 mg / bisoprolol fumarate 5 mg / perindopril arginine 5 mg

    Combination Product: Amlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg

  • Active comparator
    Group B

    Free triple therapy of amlodipine 5 mg + bisoprolol fumarate 5 mg + perindopril arginine 5 mg, given concomitantly

    Drug: Norvasc 5mg tablet · Drug: Concor 5mg tablet · Drug: Coversyl 5mg tablet

Interventions

  • Combination productAmlodipine 5mg + bisoprolol fumarate 5mg + perindopril arginine 5mg

    Drug page: Amlodipine

    1 capsule/day Oral administration

  • Norvasc (amlodipine) 5mg, 1 tablet/day

  • Concor (bisoprolol fumarate) 5mg, 1 tablet/day

  • Coversyl (perindopril arginine) 5mg, 1 tablet/day

06

What researchers measure

Primary outcomes

  1. Change from baseline of blood pressure (SBP and DBP)

    Time frame: at baseline, 4, 8 and 12 weeks

Secondary outcomes

  1. Blood pressure control rate (SBP < 140 mmHg and DBP < 90 mmHg)

    Time frame: at 4, 8 and 12 weeks

  2. Response rate for antihypertensive therapy

    Rate of patients with supine blood pressure normalized (SBP \<140 mmHg and DBP \<90 mmHg) or decrease of SBP ≥20 mmHg and/or decrease of DBP ≥10 mmHg from baseline

    Time frame: at 4, 8 and 12 weeks

  3. Assessment of patient treatment satisfaction TSQM-9 questionnaire

    Time frame: 12 weeks

07

Study locations

15 sites
  • Regional state budget health care institution "Altai Regional Cardiological dispensary" 46 Malakhova St.
    Barnaul, Altai Region 656055, Russian Federation
  • Problems of Cardiovascular Diseases" 6 Sosnovy Bulvar St.
    Kemerovo, 650002, Russian Federation
  • Autonomous non-profit organization "Medical Center "Alliance" 12 Molodezhnaya St., 12
    Kirovsk, 187340, Russian Federation
  • State budgetary healthcare institution of city of Moscow "City polyclinic #2 of Healthcare Department of city of Moscow" 12 Fruktovaya St.
    Moscow, 117556, Russian Federation
  • Federal State Budgetary Institution ''Ourpatient clinic #5'' of the Administration of the President of the Russian Federation 14 Plyushchikha St.
    Moscow, 119121, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "The city hospital No.38. named after N.A. Semashko" 7/2 letter A Gospitalnaya Str., Pushkin
    Saint Pertersburg, 196601, Russian Federation
  • Pavlov First Saint Petersburg State Medical University L'va Tolstogo str. 6-8
    Saint Pertersburg, 197022, Russian Federation
  • LLC "Medicinskie tekhnologii", Nevzorova street, 6/191025, Saint-Petersburg, Vosstania street, 8 lit A
    Saint Petersburg, 192148, Russian Federation
  • LLC "Strategicheskie Medicinskie Sistemy", Nevzorova street, 6
    Saint Petersburg, 192148, Russian Federation
  • Saint-Petersburg State Budgetary Healthcare Institution "City outpatient clinic №109" 8 bld. 2 Oleko Dundicha
    Saint Petersburg, 192283, Russian Federation
  • Limited Liability Company "Medical Research Institute" 25 Let. A 3 Kolya Tomchak St.
    Saint Petersburg, 196084, Russian Federation
  • Federal State Budgetary Institution "North-West Federal Medical Research Center n.a. V.A. Almazov" of the Ministry of Health of the Russian Federation 2 Akkuratova St.
    Saint Petersburg, 197341, Russian Federation
  • The Federal State Budgetary Institute "The Nikiforov Russian Center of Emergency and Radiation Medicine" The Ministry of Russian Federation for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters
    Saint Petersburg, 197374, Russian Federation
  • Limited Liability Company "MART" 54 bld. 3 Let. J Maly Prospekt V.O
    Saint Petersburg, 1991788, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "City Consulting and Diagnostic Center No. 85" 89 bld. 3 Let. A Prospekt Veteranov
    Saint-Petersburg, 198260, Russian Federation
08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2018, 7 months.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Mar 21, 2022
StartActual
May 14, 2018
Primary completionActual
Dec 18, 2018
CompletionActual
Dec 18, 2018
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05288400
Lead sponsor
Servier
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
May 14, 2018
Primary completion
Dec 18, 2018
Completion
Dec 18, 2018
Last update
Jun 5, 2025

Study contacts

Alexandra Konradi
principal investigator · Almazov National Medical Research Centre - Department of Hypertension, Saint Petersburg, Russia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion